Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen

作者：Vermeij Renee; Leffers Ninke; Melief Cornelis J; Daemen Toos; Nijman Hans W^*

来源：Current Pharmaceutical Design, 2012, 18(25): 3804-3811.

DOI：10.2174/138161212802002805

• Immunotherapy
• vaccine
• epithelial ovarian cancer
• tumor antigen
• p53
• lymphocyte
• immunization
• clinical trial

This review discusses the results of different immunization strategies, identifies possible drawbacks in study design and provides potential solutions for augmentation of clinical efficacy. A potential target for cancer immunotherapy is p53, as approximately 50% of ovarian cancer cells carry p53 mutations. Therefore we review the immunological and clinical responses observed in ovarian cancer patients vaccinated with p53 targeting vaccines in particular. In most studies antigen-specific vaccine-induced immunological responses were observed. Unfortunately, no clinical responses with significant reduction of tumor-burden have been reported. Based on the currently available results we emphasize the necessity of multimodality treatment of ovarian cancer, combining classical cytoreductive surgery, (neo) adjuvant chemotherapy, immunotherapy and/or targeted therapy.

• 出版日期2012-8